Haleon (LON:HLN) Releases Earnings Results

Haleon (LON:HLN) posted its earnings results on Thursday. The company reported GBX 18.60 EPS for the quarter, Digital Look Earnings reports. Haleon had a net margin of 9.66% and a return on equity of 6.54%.

Haleon Price Performance

Shares of HLN traded up GBX 15.30 during trading hours on Thursday, hitting GBX 393.20. 33,161,078 shares of the company were exchanged, compared to its average volume of 39,735,855. The company has a debt-to-equity ratio of 53.36, a current ratio of 0.84 and a quick ratio of 0.93. The company has a market capitalization of £35.02 billion, a PE ratio of 23.54, a PEG ratio of 1.49 and a beta of 0.19. The firm has a fifty day simple moving average of GBX 382.12 and a 200-day simple moving average of GBX 364.77. Haleon has a one year low of GBX 325.10 and a one year high of GBX 419.50.

Analysts Set New Price Targets

HLN has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft cut their target price on Haleon from GBX 340 to GBX 335 and set a “buy” rating on the stock in a research note on Thursday, January 22nd. Berenberg Bank increased their target price on shares of Haleon from GBX 507 to GBX 517 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a GBX 370 price target on shares of Haleon in a research note on Friday, October 31st. JPMorgan Chase & Co. upped their target price on Haleon from GBX 315 to GBX 335 and gave the stock an “underweight” rating in a research report on Wednesday, November 26th. Finally, Jefferies Financial Group restated a “buy” rating and issued a GBX 450 price objective on shares of Haleon in a report on Wednesday, January 21st. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of GBX 407.83.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.